Genitrix has announced that HY-50 Vet^®, a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use.

Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function. 

Genitrix also says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load.  Injected intravenously, the product will also benefit horses with multiple joint injuries.

HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate.  It costs £55.50.

Rob Watkins, Marketing Director of Genitrix, said: "The efficacy of sodium hyaluronate is well established and we're delighted to be able to offer the IV route of administration.  We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer."

"Perhaps most importantly, in these financially difficult times, the high concentration of the product makes it a cost-effective approach compared with competitive products.  We believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments."

For further information, see http://www.genitrix.co.uk/ or ring 01403 786345.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.